Pharmacogenetics of anthracyclines

Judit C. Sági, Nóra Kutszegi, Andrea Kelemen, Lili E. Fodor, András Gézsi, Gábor T. Kovács, Dániel J. Erdélyi, C. Szalai, Ágnes F. Semsei

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.

Original languageEnglish
Pages (from-to)1075-1087
Number of pages13
JournalPharmacogenomics
Volume17
Issue number9
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Pharmacogenetics
Anthracyclines
Literature
Antineoplastic Agents
Survivors
Neoplasms
Pediatrics
Drug Therapy
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • anthracycline
  • cancer
  • cardiotoxicity

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Sági, J. C., Kutszegi, N., Kelemen, A., Fodor, L. E., Gézsi, A., Kovács, G. T., ... Semsei, Á. F. (2016). Pharmacogenetics of anthracyclines. Pharmacogenomics, 17(9), 1075-1087. https://doi.org/10.2217/pgs-2016-0036

Pharmacogenetics of anthracyclines. / Sági, Judit C.; Kutszegi, Nóra; Kelemen, Andrea; Fodor, Lili E.; Gézsi, András; Kovács, Gábor T.; Erdélyi, Dániel J.; Szalai, C.; Semsei, Ágnes F.

In: Pharmacogenomics, Vol. 17, No. 9, 01.06.2016, p. 1075-1087.

Research output: Contribution to journalReview article

Sági, JC, Kutszegi, N, Kelemen, A, Fodor, LE, Gézsi, A, Kovács, GT, Erdélyi, DJ, Szalai, C & Semsei, ÁF 2016, 'Pharmacogenetics of anthracyclines', Pharmacogenomics, vol. 17, no. 9, pp. 1075-1087. https://doi.org/10.2217/pgs-2016-0036
Sági JC, Kutszegi N, Kelemen A, Fodor LE, Gézsi A, Kovács GT et al. Pharmacogenetics of anthracyclines. Pharmacogenomics. 2016 Jun 1;17(9):1075-1087. https://doi.org/10.2217/pgs-2016-0036
Sági, Judit C. ; Kutszegi, Nóra ; Kelemen, Andrea ; Fodor, Lili E. ; Gézsi, András ; Kovács, Gábor T. ; Erdélyi, Dániel J. ; Szalai, C. ; Semsei, Ágnes F. / Pharmacogenetics of anthracyclines. In: Pharmacogenomics. 2016 ; Vol. 17, No. 9. pp. 1075-1087.
@article{f222b4f32a2042e1abf95846af9312ec,
title = "Pharmacogenetics of anthracyclines",
abstract = "Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.",
keywords = "anthracycline, cancer, cardiotoxicity",
author = "S{\'a}gi, {Judit C.} and N{\'o}ra Kutszegi and Andrea Kelemen and Fodor, {Lili E.} and Andr{\'a}s G{\'e}zsi and Kov{\'a}cs, {G{\'a}bor T.} and Erd{\'e}lyi, {D{\'a}niel J.} and C. Szalai and Semsei, {{\'A}gnes F.}",
year = "2016",
month = "6",
day = "1",
doi = "10.2217/pgs-2016-0036",
language = "English",
volume = "17",
pages = "1075--1087",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Pharmacogenetics of anthracyclines

AU - Sági, Judit C.

AU - Kutszegi, Nóra

AU - Kelemen, Andrea

AU - Fodor, Lili E.

AU - Gézsi, András

AU - Kovács, Gábor T.

AU - Erdélyi, Dániel J.

AU - Szalai, C.

AU - Semsei, Ágnes F.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.

AB - Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.

KW - anthracycline

KW - cancer

KW - cardiotoxicity

UR - http://www.scopus.com/inward/record.url?scp=84977673695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977673695&partnerID=8YFLogxK

U2 - 10.2217/pgs-2016-0036

DO - 10.2217/pgs-2016-0036

M3 - Review article

VL - 17

SP - 1075

EP - 1087

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 9

ER -